Occam Places Jorge Bartolome as CEO at Areteia Therapeutics
Areteia Therapeutics, a private clinical stage biotech that just raised $350M in a Series A led by Bain Capital, is the product of a collaboration between Clive Meanwell’s Population Health Partners and Knopp Biosciences. The recent robust financing round will be used to advance its lead candidate, dexpramipexole, a small molecule in phase 3 development, one holding out great promise as the first oral therapy for asthma. If successful, this compound represents a potential game changing treatment for an ubiquitous and difficult to treat chronic condition.
Jorge enters the fray at a critical point in the company’s evolution. He brings powerful domain expertise and decades of commercial leadership to the party. Previously, Bartolome served as President of Canada for Janssen and, prior to that, as SVP of the US Respiratory Business Unit of GSK.
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.